

Jerome Henri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4216800/publications.pdf>

Version: 2024-02-01

17
papers

235
citations

1163117

8
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

345
citing authors

#	ARTICLE	IF	CITATIONS
1	Low or High Doses of Cefquinome Targeting Low or High Bacterial Inocula Cure <i>Klebsiella pneumoniae</i> Lung Infections but Differentially Impact the Levels of Antibiotic Resistance in Fecal Flora. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1744-1748.	3.2	37
2	A physiologically based pharmacokinetic model for chickens exposed to feed supplemented with monensin during their lifetime. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 370-382.	1.3	35
3	Liquid chromatography-electrospray tandem mass spectrometric method for quantification of monensin in plasma and edible tissues of chicken used in pharmacokinetic studies: Applying a total error approach. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 850, 15-23.	2.3	31
4	Comparative Cytotoxicity, Oxidative Stress, and Cytokine Secretion Induced by Two Cyanotoxin Variants, Microcystin LR and RR, in Human Intestinal Caco-2 Cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2013, 27, 253-258.	3.0	24
5	Bioavailability, distribution and depletion of monensin in chickens. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2009, 32, 451-456.	1.3	17
6	Comparison of the oral bioavailability and tissue disposition of monensin and salinomycin in chickens and turkeys. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2012, 35, 73-81.	1.3	15
7	Low in vitro permeability of the cyanotoxin microcystin-LR across a Caco-2 monolayer: With identification of the limiting factors using modelling. <i>Toxicol</i> , 2014, 91, 5-14.	1.6	11
8	Tools to evaluate pharmacokinetics data for establishing maximum residue limits for approved veterinary drugs: examples from JECFA's work. <i>Drug Testing and Analysis</i> , 2016, 8, 565-571.	2.6	11
9	A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion. <i>Pharmaceutical Research</i> , 2018, 35, 92.	3.5	10
10	Cytochrome P450-dependent metabolism of monensin in hepatic microsomes from chickens and turkeys. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2008, 31, 584-586.	1.3	8
11	The present and future of withdrawal period calculations for milk in the European Union: dealing with data below the limit of quantification. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 116-122.	1.3	6
12	The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 218-230.	1.3	6
13	A PBPK model to study the transfer of $\hat{1}\pm$ -hexabromocyclododecane ($\hat{1}\pm$ -HBCDD) to tissues of fast- and slow-growing broilers. <i>Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment</i> , 2020, 37, 316-331.	2.3	6
14	Permeability of the Cyanotoxin Microcystin-RR across a Caco-2 Cells Monolayer. <i>Toxins</i> , 2021, 13, 178.	3.4	6
15	Lack of experimental evidence to support mcr-1 -positive <i>Escherichia coli</i> strain selection during oral administration of colistin at recommended and higher dose given by gavage in weaned piglets. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 128-131.	2.5	5
16	Permeability of dihydro- and cysteine-brevetoxin metabolites across a Caco-2 cell monolayer. <i>Harmful Algae</i> , 2014, 32, 22-26.	4.8	4
17	Implementation and assessment of the quality management system in research in a laboratory of the French Food Safety Agency: application to PhD student work. <i>Accreditation and Quality Assurance</i> , 2009, 14, 207-217.	0.8	3